Page 24 - Biocon

Biocon falls over 10% in five trading days

The stock dipped 5% to Rs 1,031, extending its 6.8% decline in past four trading days on the BSE.

Biosimilars portfolio monetisation key for Biocon

Biocon's results for the quarter ending March 2017 was muted due to longer timelines for product approvals in some emerging markets, discontinuance of some in-licensed products and impact of the fire at Syngene, its subsidiary.The research arm, Syngene, which contributed about 30 per cent to overall sales, saw a 14 per cent year-on-year decline in business in March quarter as a fire incident in December last year led to a temporary disruption. The small molecules and biologics business, contributing about half to revenues, also saw flat sales. Only branded formulations saw good growth of 25 per cent, but since it forms only 15 per cent of revenues, it was not enough to prevent overall sales from declining two per cent year-on-year to Rs 925 crore. Bloomberg consensus estimates had pegged revenues at Rs 1,061 crore.With lower sales, Ebitda at Rs 182 crore came significantly lower than estimates of Rs 253 crore. So did net profit, which at Rs 127 crore missed consensus estimates of Rs ..

Biocon Q4 net up 75% at Rs 135 cr

Issues bonus shares in the ratio of 2:1

Biocon board to consider bonus issue today; shares jump nearly 10%

Biocon's stock zoomed 9.57 per cent to touch its one-year high of Rs 1,168 on BSE

Biocon surges 5% on bonus issue plan

The board will meet on April 27, to consider bonus issue shares

Setback for Roche: Mylan, Biocon can now sell generics of its cancer drug

Delhi HC also allows them to use Trastuzumab data for breast, metastatic & gastric cancer therapy

Biocon sees growth from new markets, no risk from USFDA biosimilar norms

The biologics segment was the main contributor to revenue and grew 61 per cent y-o-y

Biocon's Q3 profits rise by 65% to Rs 171 cr

The company's businesses in Japan, emerging markets have been witnessing high growth

Strong growth prospects: In Biocon, investors see a blockbuster pipeline

US nod to application for breast cancer drug is latest positive for the stock

Biocon hits new high after USFDA accepts cancer drug biosimilar application

The stock rallied nearly 5% to Rs 1,050 also its fresh record high on the BSE in early morning trade

USFDA accepts Biocon cancer drug biosimilar application

FDA decision likely in September; drug is similar to branded Trastuzumab, which treats breast cancer

India's Biocon ranks among the top 10 employers in biotechnology industry

Of the top 10 employers, six are based in the US, two in Denmark and one in Switzerland.

After run-up, Biocon stock may catch its breath

Immense long-term potential; but caution sets in as potential regulatory hurdles loom

Biocon profit at Rs 147 cr, revenue up 21%

Expansion of our biologics footprint in emerging markets and licensing agreements boosted the revenue further, says Kiran Mazumdar-Shaw

Biocon hits record high on strong Q2 earnings

The stock up 4% to Rs 1,020 after the company posted 52% YoY jump in consolidated net profit at Rs 147 crore in Q2FY17.

Biocon: Scope for long-term gains

There is little doubt about the strength of the company's biosimilar portfolio but upsides are a couple of years away

Biocon appoints Suresh Subramanian head of its branded formulations business

The division is focused on the chronic therapy areas such as diabetes, cancer and autoimmune conditions

Suresh Subramanian to head Biocon's branded formulations biz

Biocon's Branded Formulations (India) business is a biologics-led, speciality pharma business

Biocon hits fresh record high as EMA accepts biosimilar for review

The stock hit a fresh record high of Rs 910, up 5% on the BSE in early morning trade.

European Medical Agency to review Biocon-Mylan's anti cancer biosimilar

This is the partnership's second biosimilar submission that is accepted for review in Europe